(1) Department of Pulmonary Disease, Shanghai Chest Hospital, 241#, West Huaihai Road, Shanghai, China;
Abstract:
Background
Lung cancer is the leading cause for cancer-related mortality and morbidity, and the survival of late-stage non-small cell
lung cancer (NSCLC) remains poor. We hereby evaluate conventional chemotherapy followed by immunotherapy using dendritic cells
and cytokine-induced killer cells in the treatment for late stage of NSCLC.